|
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Clinical research trials and Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia. Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia clinical trial. Human subjects often obtain the finest healthcare possible for their Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "L" Clinical Trials Conditions > Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia  Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
For Condition: Eye Cancer,Lymphoma,Leukemia
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Jonsson Comprehensive Cancer Center
Synopsis: RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of neutropenia in patients who are being treated for cancer. It is not yet known whether levofloxacin is more effective than cefepime in reducing fever and controlling symptoms of neutropenia. PURPOSE: Randomized phase III trial to compare the effectiveness of levofloxacin with that of cefepime in reducing fever and controlling symptoms of neutropenia in patients who are being treated for cancer.
Details: OBJECTIVES: I. Compare the safety and efficacy of levofloxacin versus cefepime in cancer patients with fever and neutropenia. II. Compare the percentage of patients whose fever defervesces and who have no signs or symptoms of infection with and without therapeutic modification. III. Compare the percentage of survival of patients treated with these 2 regimens with no therapeutic modifications. IV. Compare the overall survival of patients treated with these 2 regimens regardless of therapeutic modifications. V. Compare the time to resolution of fever in patients treated with these regimens. VI. Compare the microbiologic response by pathogen and site of infection in patients treated with these regimens. VII. Compare the percentage of patients whose fever defervesces only after resolution of neutropenia (absolute neutrophil count at least 500/mm3) with no therapeutic modification. PROTOCOL OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified according to type of malignancy (solid tumor, including lymphoma vs leukemia), prior prophylactic antibiotics (yes vs no), and participating center. Patients are randomized to one of two treatment arms. Arm I: Patients receive levofloxacin IV over 90 minutes once daily for 14-28 days. Arm II: Patients receive cefepime IV over 30 minutes every 8 hours for 14-28 days. Patients may receive additional antifungal, antibacterial, or antiviral therapy if condition has deteriorated, no response is seen in 72 hours, or and infection is suspected or documented. Patients are followed at 1-3 and 7-12 days and then at 3-4 weeks. PROJECTED ACCRUAL: Approximately 260-400 patients (130-200 per treatment arm) will be accrued for this study.
Eligibility:
Study Type: Interventional, Educational/Counseling/Training
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Diagnosis of malignancy; Solid tumor (including lymphoma) or leukemia - Hospitalized and anticipated to remain hospitalized during study - Febrile defined as oral temperature of at least 100.4 degrees F (38 degrees C) on 2 occasions within 24 hours OR at least 100.8 degrees F (38.2 degrees C) on a single reading; No obvious noninfectious cause of fever (e.g., platelet transfusion) - Neutropenic, defined as absolute neutrophil count (ANC) currently less than 500/mm3 OR anticipated to be less than 500/mm3 within 24 hours of study entry; Anticipated ANC to be less than 500/mm3 for at least 72 hours; No neutropenia unassociated with malignancy; No chronic neutropenia; No neutropenia anticipated to last more than 14 days - No acute myelogenous leukemia unless receiving consolidation chemotherapy or induction dose that does not prolong neutropenia for more than 3 weeks - No infection due to an identified organism - No high likelihood of infection due to anaerobic organisms, including intra-abdominal infections or perirectal abscess at admission - No known osteomyelitis - No requirement for new antifungal agent --Prior/Concurrent Therapy-- - Biologic therapy: No prior sargramostim (GM-CSF) or filgrastim (G-CSF) for current course of chemotherapy; Concurrent GM-CSF or G-CSF allowed if neutropenia lasts at least 3 days - Chemotherapy: See Disease Characteristics - Endocrine therapy: Not specified - Radiotherapy: Not specified - Surgery: Not specified - Other: No prior treatment under this protocol; No prior prophylactic anti-infectives other than acyclovir or sulfamethoxazole with trimethoprim; At least 72 hours since prior systemic antibiotics (except prophylactic sulfamethoxazole with trimethoprim); At least 30 days since prior experimental drug or medical device (except drugs currently marketed in the United States for the treatment of the malignancy); No other concurrent systemic antibacterial agents; No concurrent topical antimicrobial agents --Patient Characteristics-- - Age: 18 and over - Performance status: Not specified - Life expectancy: At least 14 days - Hematopoietic: See Disease Characteristics - Hepatic: Not specified - Renal: Creatinine clearance at least 20 mL/min; No oliguria (urine output less than 20 mL/hour) unresponsive to fluid challenge - Cardiovascular: No shock or hypotension (supine systolic blood pressure less than 80 mmHg) unresponsive to fluid challenge - Other: Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception; No HIV infection with CD4 counts less than 200/mm3; No significant risk for seizures; No unstable psychiatric disorder; Weight greater than 40 kg; No prior allergic or severe adverse reaction to study drugs or to any member of the quinolone or beta-lactam class of antibacterials; No disorder or disease that would preclude study
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MaryTerrito, Study Chair, Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
United States
Additional Information:
Study ID Numbers: CDR0000068726; NCI-G01-1965,MCNEIL-CAPSS-118,UCLA-0006093
Study Start Date: September 2001
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00020865
Other Eye Cancer Studies:
1. Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
2. ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma
3. Stem Cell Transplantation in Treating Patients with Hematologic Cancer
4. Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
5. Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation
Related Studies:
Other Eye Cancer Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
|
|
|
|
|
|
|
|
